title: Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.
abstract: The discovery of anaplastic lymphoma kinase (ALK) rearrangements in a subset of patients with nonsmall- cell lung cancer (NSCLC) and its potential blockage by specific inhibitors such as crizotinib has been one of the latest advances in the treatment of this disease. In this article, we will review the most important clinical aspects of ALK alterations in NSCLC patients and the pending questions to answer: the most effective means of diagnosing ALK-rearranged NSCLC, and efficacy, toxicity profile and potential mechanisms of resistance to crizotinib.
authors.affiliation: Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain. jcastro.hulp@salud.madrid.org
authors.forename: J
authors.initials: J
authors.lastname: de Castro-Carpeño
authors.forename: R
authors.initials: R
authors.lastname: Perona
authors.forename: C
authors.initials: C
authors.lastname: Belda-Iniesta
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology; D000077547:Crizotinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
references.citation: Blood. 2009 Jul 9;114(2):360-70
references.pmid: 19423729
references.citation: Cell. 2007 Dec 14;131(6):1190-203
references.pmid: 18083107
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3691-702
references.pmid: 12202671
references.citation: Genomics. 2000 Sep 15;68(3):348-50
references.pmid: 10995578
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4247-53
references.pmid: 19667264
references.citation: N Engl J Med. 2010 Oct 28;363(18):1734-9
references.pmid: 20979473
references.citation: Nat Rev Cancer. 2008 Jan;8(1):11-23
references.pmid: 18097461
references.citation: Rom J Morphol Embryol. 2010;51(4):647-53
references.pmid: 21103621
references.citation: Hum Pathol. 1996 Jun;27(6):590-4
references.pmid: 8666370
references.citation: Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22
references.pmid: 18089725
references.citation: Clin Cancer Res. 2011 Dec 1;17(23):7394-401
references.pmid: 21948233
references.citation: Clin Cancer Res. 2011 Dec 1;17(23):7213-8
references.pmid: 22010214
references.citation: N Engl J Med. 2010 Oct 28;363(18):1693-703
references.pmid: 20979469
references.citation: Cell Mol Life Sci. 2004 Dec;61(23):2939-53
references.pmid: 15583856
references.citation: Neoplasia. 2008 Mar;10(3):298-302
references.pmid: 18320074
references.citation: Oncogene. 1994 Jun;9(6):1567-74
references.pmid: 8183550
references.citation: J Cell Physiol. 2004 Jun;199(3):330-58
references.pmid: 15095281
references.citation: Nature. 2008 Oct 16;455(7215):975-8
references.pmid: 18923525
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907
references.pmid: 20647400
references.citation: Biochemistry. 2010 Aug 17;49(32):6813-25
references.pmid: 20695522
references.citation: Cancer Res. 2008 Jul 1;68(13):4971-6
references.pmid: 18593892
references.citation: Biochem J. 2010 Sep 15;430(3):425-37
references.pmid: 20632993
references.citation: Nature. 2007 Aug 2;448(7153):561-6
references.pmid: 17625570
references.citation: Clin Cancer Res. 2009 Aug 15;15(16):5216-23
references.pmid: 19671850
references.citation: Clin Cancer Res. 2009 May 1;15(9):3143-9
references.pmid: 19383809
references.citation: Science. 1994 Mar 4;263(5151):1281-4
references.pmid: 8122112
references.citation: Clin Cancer Res. 2008 Oct 15;14(20):6618-24
references.pmid: 18927303
references.citation: Lancet Oncol. 2011 Oct;12(11):1004-12
references.pmid: 21933749